ESMO 2024: Ribociclib Improves Invasive Disease-Free Survival in HR-Positive/HER2-Negative Early Breast Cancer
The benefit persisted one year after the end of three years of ribociclib treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.